Skip to main content
. 2018 May 1;8(1):83–87. doi: 10.5005/jp-journals-10018-1268

Table 4: Subgroup analysis of additional benefit of serum AFP for HCC detection

          HCC detection (%)                    
With HCC           US positive      US and/or AFP positive      p-value*      ADR (%)      NND     
Total (452)      150      122 (81.3)      145 (96.7)      <0.001      15.3      20     
CHB** (254)      69      54 (78.3)      66 (95.7)        0.002      17.4      22     
• With cirrhosis (154)      54      40 (74.1)      51 (94.4)        0.004      20.4      14     
• No cirrhosis (100)      15      14 (93.3)      15 (100)        0.308      6.7      100     
CHC*** (129)      61      50 (82.0)      60 (98.4)        0.002      16.4      13     
Alcoholic cirrhosis (33)      8      7 (87.5)      8 (100)        0.302      12.5      33     
Cryptogenic cirrhosis (18)      7      5 (71.4)      6 (85.7)        0.515      14.3      18     

*Z-test comparing proportion of US positive vs US and/or AFP positive; **including CHB/CHC coinfection and CHB with alcoholic cirrhosis; ***including CHC with alcoholic cirrhosis; CHB: Chronic hepatitis B; CHC: Chronic hepatitis C; ADR: Additional detection rate